Deutetrabenazine (trade name Austedo) is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.

Deutetrabenazine 24 mg/day and 36 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerability.

These findings suggest that dosing regimens could be individualized and tailored for patients on the basis of dyskinesia control and tolerability.

[citation needed] Teva Pharmaceuticals received approval from the Food and Drug Administration to market deutetrabenazine in early 2017, along with five years of orphan drug exclusivity for the treatment of chorea associated with Huntington's disease.